

KACIAN DANIEL L  
 Form 4  
 August 02, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**KACIAN DANIEL L**

(Last) (First) (Middle)

**GEN-PROBE  
 INCORPORATED, 10210  
 GENETIC CENTER DRIVE**

(Street)

**SAN DIEGO, CA 92121**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**GEN PROBE INC [GPRO]**

3. Date of Earliest Transaction  
 (Month/Day/Year)  
**08/01/2012**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
**Exec. VP, Chief Scientist**

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/01/2012		D	(A) or (D) D	Amount 77,904 (1) Price \$ 82.75	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: KACIAN DANIEL L - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 36.59	08/01/2012		D		50,000		<u>(2)</u>	09/13/2014	Common Stock	50,000
Stock Option (Right to Buy)	\$ 42.5	08/01/2012		D		30,000		<u>(2)</u>	10/17/2015	Common Stock	30,000
Stock Option (Right to Buy)	\$ 49.29	08/01/2012		D		32,000		<u>(2)</u>	08/15/2013	Common Stock	32,000
Stock Option (Right to Buy)	\$ 60.82	08/01/2012		D		25,000		<u>(2)</u>	08/15/2014	Common Stock	25,000
Stock Option (Right to Buy)	\$ 60.15	08/01/2012		D		18,750		<u>(2)</u>	08/15/2015	Common Stock	18,750
Stock Option (Right to Buy)	\$ 38.51	08/01/2012		D		16,300		<u>(2)</u>	08/17/2016	Common Stock	16,300
Stock Option (Right to Buy)	\$ 42.66	08/01/2012		D		33,000		<u>(2)</u>	02/10/2017	Common Stock	33,000
Stock Option (Right to Buy)	\$ 63.8	08/01/2012		D		27,583		<u>(2)</u>	02/10/2018	Common Stock	27,583
Stock Option (Right to Buy)	\$ 69.22	08/01/2012		D		30,637		<u>(3)</u>	02/10/2019	Common Stock	30,637
Performance Stock Rights	\$ 0	08/01/2012		D		3,134		<u>(5)</u>	02/10/2014	Common Stock	3,134
Performance Stock Rights	\$ 0	08/01/2012		D		12,564		<u>(6)</u>	02/10/2015	Common Stock	12,564

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KACIAN DANIEL L GEN-PROBE INCORPORATED 10210 GENETIC CENTER DRIVE SAN DIEGO, CA 92121			Exec. VP, Chief Scientist	

## Signatures

/s/ Andrew S. Greenhalgh,  
Attorney-in-Fact

08/02/2012

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The amount reported includes an aggregate of 211 shares of common stock acquired under the Registrant's Employee Stock Purchase Plan since the Reporting Person last filed a Form 4 with the Securities and Exchange Commission.

This stock option was canceled pursuant to the Agreement and Plan of Merger, dated as of April 29, 2012, by and among the Registrant, Hologic, Inc. ("Hologic"), and Gold Acquisition Corp. (the "Merger Agreement"), in exchange for a payment in cash, without interest and

- (2) less the amount of any required tax withholding, equal to the product of: (i) the excess of \$82.75 (the per share merger consideration pursuant to the Merger Agreement) over the exercise price of the stock option; and (ii) the number of shares of common stock of the Registrant underlying the stock option.

- (3) 25% of the shares subject to the stock option vest on February 10, 2013, and the remaining shares vest in equal monthly installments over the following three years.

Pursuant to the Merger Agreement, these options were assumed by Hologic and converted into options to acquire that number of shares of Hologic common stock which is equal to the number of shares of common stock of the Registrant subject to such options immediately prior to the merger multiplied by 4.51174963 with a per share exercise price equal to the quotient determined by dividing the per share exercise price of such options immediately prior to the merger by 4.51174963.

- (4) Hologic common stock which is equal to the number of shares of common stock of the Registrant subject to such options immediately prior to the merger multiplied by 4.51174963 with a per share exercise price equal to the quotient determined by dividing the per share exercise price of such options immediately prior to the merger by 4.51174963.
- (5) The performance stock rights were canceled pursuant to the Merger Agreement and converted into the right to receive a payment in cash, without interest and less the amount of any required tax withholding, equal to the product of: (i) \$82.75 (the per share merger consideration pursuant to the Merger Agreement); and (ii) 4,701 (which amount equals 150% of the target number of shares of common stock of the Registrant underlying the performance stock rights).

- (6) The performance stock rights were canceled pursuant to the Merger Agreement and converted into the right to receive a payment in cash, without interest and less the amount of any required tax withholding, equal to the product of: (i) \$82.75 (the per share merger consideration pursuant to the Merger Agreement); and (ii) 9,423 (which amount equals 150% of the target number of shares of common stock of the Registrant underlying the performance stock rights).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.